GlassScriptPhysician profile
Jessica Morris
NPI 1417599010
$2,793.03
in general payments reported to CMS, 2019-2025
20 companies · $1,150 in 2025
The $1,150 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $240 · 2023: $373 · 2024: $1,030 · 2025: $1,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,528 · Education: $24.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,528.30 |
| Education | $24.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $558.57 | 2023-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $465.35 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $279.18 | 2023-2025 | Ultomiris |
| Ardelyx, INC. | $221.15 | 2024-2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $189.82 | 2022-2025 | Farxiga |
| Akebia Therapeutics INC | $189.39 | 2022-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $179.79 | 2023-2025 | |
| Novo Nordisk INC | $134.08 | 2024-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.40 | 2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $92.40 | 2024-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $69.99 | 2023-2025 | Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $61.95 | 2024-2025 | |
| Pfizer INC. | $45.63 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $37.34 | 2024 | Quviviq |
| Vantive US Healthcare LLC | $30.62 | 2025 | Renal - Pd |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $26.78 | 2025 | Acthar |
| Calliditas Therapeutics US INC. | $24.08 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $22.59 | 2025 | Jynarque |
| Daiichi Sankyo INC. | $22.38 | 2024 | Injectafer |
| Cormedix INC. | $19.54 | 2025 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.